Tatmeen is the UAE’s national track-and-trace system for pharmaceuticals, run under MOHAP with GS1 UAE. Every pack placed on the UAE market carries a serialised 2D DataMatrix (GTIN, serial number, batch, expiry) and each supply-chain hand-over — manufacturer to importer, importer to distributor, distributor to hospital or pharmacy, and dispensing to the patient — is reported to the platform. The aim is to shut out falsified medicines and to see where stock is.
What changes for a hospital or pharmacy
- Receiving. Goods are scanned at the pack or aggregated case level on receipt; the shipment is accepted in Tatmeen before stock is put away. A receipt that does not match the advance notice is held.
- Dispensing. Packs are decommissioned (marked as dispensed) at the point of dispensing; partial-pack and ward-stock processes need a defined scan point.
- Returns and destruction. Reported as events, not just paperwork.
- Systems. The pharmacy or ERP system either integrates with Tatmeen via its interface or staff use the Tatmeen app; integration is the sustainable route for any hospital above a few hundred beds.
What changes for suppliers and importers
Serialised packaging from the manufacturer; aggregation data (which packs are in which case/pallet); shipment notifications; and a local authorised party that commissions products in Tatmeen. Exporters to the UAE who cannot provide serialised, aggregated product data are effectively out of the market.
Procurement implications
Tender documents should require Tatmeen compliance and aggregation data as a pass/fail criterion. Receiving KPIs change: scan rate, exceptions per shipment, time to acceptance. And the data is a gift — a hospital integrated with Tatmeen has batch-level consumption and expiry visibility it never had before. Saudi Arabia’s RSD (Drug Track and Trace) system follows the same logic; suppliers to the Gulf should plan for both.